Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.
Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for select patients.
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...
Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...
GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...
Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results